PL378421A1 - Pochodne kwasu 10,10-dialkiloprostanowego jako środki do obniżania ciśnienia śródgałkowego - Google Patents

Pochodne kwasu 10,10-dialkiloprostanowego jako środki do obniżania ciśnienia śródgałkowego

Info

Publication number
PL378421A1
PL378421A1 PL378421A PL37842104A PL378421A1 PL 378421 A1 PL378421 A1 PL 378421A1 PL 378421 A PL378421 A PL 378421A PL 37842104 A PL37842104 A PL 37842104A PL 378421 A1 PL378421 A1 PL 378421A1
Authority
PL
Poland
Prior art keywords
agents
acid derivatives
intraocular pressure
glaucoma
prostanoic acid
Prior art date
Application number
PL378421A
Other languages
English (en)
Other versions
PL209130B1 (pl
Inventor
Yariv Donde
Jeremiah H. Nguyen
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/365,369 external-priority patent/US6875787B2/en
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Publication of PL378421A1 publication Critical patent/PL378421A1/pl
Publication of PL209130B1 publication Critical patent/PL209130B1/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/08Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Wynalazek dotyczy sposobu leczenia nadciśnienia śródgałkowego lub jaskry, polegającego na podawaniu pacjentowi cierpiącemu na nadciśnienie śródgałkowe lub jaskrę skutecznej ilości związku o ogólnym wzorze (I), w którym linia kreskowana oznacza ewentualnie obecne wiązanie, kreskowany klin oznacza konfigurację wiązania skierowanego w dół (α), pełny trójkąt oznacza konfigurację wiązania skierowanego w górę (β); n oznacza 0-6; X oznacza CH2, S lub O; Y oznacza ugrupowanie farmaceutycznie dopuszczalnej soli CO2H, lub CO2R, CONR2, CONHCH2CH2OH, CON (CH2CH2OH)2, CH2OR, P(O)(OR)2, CONRSO2R, i SONR2, albo 1-R-podstawiony tetrazolil-5; R oznacza H, C1-6-alkil lub C2-6-alkenyl; R2 i R3 oznaczają liniowe C1-6-alkile, takie same lub różne, które mogą być związane ze sobą z utworzeniem pierścienia zawierającego atom węgla, do którego są przyłączone.
PL378421A 2003-02-11 2004-02-06 Pochodne kwasu 10,10-dialkiloprostanowego, roztwór do stosowania w okulistyce, sposób wytwarzania związków pośrednich i zastosowanie pochodnych kwasu 10,10-dialkiloprostanowego PL209130B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/365,369 US6875787B2 (en) 2003-02-11 2003-02-11 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
US10/772,720 US20040235958A1 (en) 2003-02-11 2004-02-04 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure

Publications (2)

Publication Number Publication Date
PL378421A1 true PL378421A1 (pl) 2006-04-03
PL209130B1 PL209130B1 (pl) 2011-07-29

Family

ID=32871611

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378421A PL209130B1 (pl) 2003-02-11 2004-02-06 Pochodne kwasu 10,10-dialkiloprostanowego, roztwór do stosowania w okulistyce, sposób wytwarzania związków pośrednich i zastosowanie pochodnych kwasu 10,10-dialkiloprostanowego

Country Status (12)

Country Link
EP (1) EP1608309B1 (pl)
JP (1) JP5319065B2 (pl)
KR (1) KR101077461B1 (pl)
AU (1) AU2004211936B2 (pl)
BR (1) BRPI0407400A (pl)
CA (1) CA2515631C (pl)
MX (1) MXPA05008431A (pl)
NO (1) NO334659B1 (pl)
NZ (1) NZ541352A (pl)
PL (1) PL209130B1 (pl)
RU (1) RU2336081C2 (pl)
WO (1) WO2004071428A2 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7855226B2 (en) 2003-02-11 2010-12-21 Allergan, Inc. Treatment of inflammatory bowel disease
CA2585367A1 (en) * 2004-10-26 2006-05-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
AU2012200514B2 (en) * 2005-03-17 2014-03-06 Allergan, Inc. Treatment of inflammatory bowel disease
PL2084124T3 (pl) * 2006-10-02 2014-08-29 Techfields Biochem Co Ltd Dodatnio naładowane rozpuszczalne w wodzie proleki prostaglandyn i związków pokrewnych o bardzo dużych szybkościach przenikania przez skórę
CN105566192B (zh) * 2006-10-02 2019-01-22 于崇曦 具有快速皮肤穿透速度的带正电荷的水溶性的前列腺素及相关化合物的前药
US8455547B2 (en) * 2008-02-05 2013-06-04 Allergan, Inc. Substituted cyclopentanes having prostaglandin activity
US7732443B2 (en) * 2008-03-18 2010-06-08 Yariv Donde Therapeutic substituted cyclopentanes
WO2009137345A1 (en) * 2008-05-09 2009-11-12 Allergan, Inc. Therapeutic compounds
EP2488168A1 (en) 2009-10-14 2012-08-22 Gemmus Pharma Inc. Combination therapy treatment for viral infections
CN103068382A (zh) * 2010-07-30 2013-04-24 阿勒根公司 用于皮肤修复的化合物和方法
SG187861A1 (en) * 2010-08-17 2013-03-28 Allergan Inc Ep2 or ep4 agonists for treating corneal haze
AU2014305843B2 (en) 2013-08-09 2019-08-29 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117014A (en) 1976-01-09 1978-09-26 Abbott Laboratories Prostaglandin derivatives
JPS59101458A (ja) * 1982-12-01 1984-06-12 Nippon Iyakuhin Kogyo Kk 新規なチアプロスタグランジン誘導体及びその製法
JPS632972A (ja) * 1986-06-20 1988-01-07 Nippon Iyakuhin Kogyo Kk 新規プロスタグランジンe↓1誘導体及びその製法
US5462968A (en) * 1994-01-19 1995-10-31 Allergan, Inc. EP2 -receptor agonists as agents for lowering intraocular pressure
US5877211A (en) * 1997-11-21 1999-03-02 Allergan EP2 receptor agonists as neuroprotective agents for the eye
US6410591B1 (en) * 2001-05-08 2002-06-25 Allergan Sales, Inc. 3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
US6531504B2 (en) * 2001-05-17 2003-03-11 Allergan, Inc. Prostanoic acid derivatives as agents for lowering intraocular pressure
AU2002259210B2 (en) * 2001-06-14 2007-11-08 Allergan, Inc. 3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure

Also Published As

Publication number Publication date
NO334659B1 (no) 2014-05-12
AU2004211936A1 (en) 2004-08-26
RU2005129072A (ru) 2006-02-27
CA2515631A1 (en) 2004-08-26
EP1608309B1 (en) 2012-07-11
BRPI0407400A (pt) 2006-02-21
JP5319065B2 (ja) 2013-10-16
WO2004071428A3 (en) 2005-11-10
PL209130B1 (pl) 2011-07-29
JP2006517587A (ja) 2006-07-27
RU2336081C2 (ru) 2008-10-20
AU2004211936B2 (en) 2008-09-11
NO20053715D0 (no) 2005-08-01
EP1608309A2 (en) 2005-12-28
NZ541352A (en) 2007-12-21
KR20050101202A (ko) 2005-10-20
CA2515631C (en) 2013-08-20
WO2004071428A2 (en) 2004-08-26
NO20053715L (no) 2005-10-27
KR101077461B1 (ko) 2011-10-26
MXPA05008431A (es) 2005-10-19

Similar Documents

Publication Publication Date Title
NO20053715L (no) 10,10-dialkylprostanoinsyrederivater som midler for a senke intraokulaert trykk
TW200512184A (en) 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
KR880007460A (ko) 3-헤테로-치환된-n-벤질-인돌
MY116542A (en) New inhibitors of platelet aggregation.
NO20050470L (no) Aminoalkoholderivater
HK1061645A1 (en) 3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
WO2003094845A3 (en) Pyridine-based thyroid receptor ligands
KR970701722A (ko) 포스폰산 디에스테르 유도체(phosphonic diester derivative)
WO2002089813A3 (en) 3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
EP0330461A3 (en) Piperidine derivatives
WO2001058866A3 (en) Ocular hypotensive lipids
DK1043310T3 (da) Biphenylamidinderivater
CA2332513A1 (fr) Nouveaux derives de 4-sulfonamides piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DK1390036T3 (da) Prostansyrederivater som midler til nedsættelse af intraokulært tryk
AU2002346671B2 (en) Aminoalkyl-benzofuran-5-OL compounds for the treatment of glaucoma
ES2172376A1 (es) Nuevos derivados de isoquinoleinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
EP0307061B1 (en) Anxiolytically active piperazine derivatives
JP2005513103A5 (pl)
US4558037A (en) Cardiovascular composition
US6127413A (en) Ocular depressor
KR920006326A (ko) 새로운 아미노산 유도체, 그것의 제조방법 및 그것을 함유하는 약학적 조성물
EA200000373A2 (ru) Новые соединения 1-аза-2-алкил-6-арилциклоалкана, способ их получения и содержащие их фармацевтические композиции
IL88573A (en) 2-plasmin inhibitor depressant, urokinase secretion accelerator or thrombolytic composition comprising trihydroxypiperidine derivatives, nojirimycin or castanospermine
ES2354516T3 (es) Derivados de pirrolid-2-ona 1,5-disustituida para su uso como agonista del receptor de ep4 en el tratamiento de enfermedades oculares tales como glaucoma.
CA2151443A1 (en) Cycloheptimidazole derivatives, method of manufacturing the same and therapeutic agents containing these compounds

Legal Events

Date Code Title Description
RECP Rectifications of patent specification